Coccidioidomycosis Outlook Highlights The Limits Of Regulatory Incentives
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.
You may also be interested in...
A $60.8m financing round gives F2G the resources to develop what it hopes will be the first new antifungal in a new class in two decades.
US FDA adds brucellosis, opisthorchiasis and paragonimiasis to the list of qualifying diseases but declines to include clonorchiasis and coccidioidomycosis, finding a significant market in developed nations for treatments or vaccines addressing the two conditions.
App allows clinicians to discuss off-label treatments, but information is intended to be hypothesis-generating, not for regulatory use.